Loading...

Purified anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_Pure_091907
Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with purified H1.2F3, followed by anti-Armenian hamster IgG FITC
  • H1dot2F3_Pure_091907
    Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with purified H1.2F3, followed by anti-Armenian hamster IgG FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
104502 500 µg 203€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  2. Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed
  3. Lu X, et al. 2021. J Exp Med. 218: . PubMed
  4. Avalos A, et al. 2022. JCI Insight. 7: . PubMed
  5. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  6. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  7. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
  8. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  9. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  10. Guo R, et al. 2020. Cell Res. 30:21. PubMed
  11. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  12. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
  13. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  14. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  15. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  16. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
  17. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  18. Kroczek AL, et al. 2019. Front Immunol. 9:2806. PubMed
  19. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  20. Pawaria S, et al. 2020. Arthritis Rheumatol. 72:359. PubMed
  21. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  22. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  23. Kiripolsky J, et al. 2021. J Autoimmun. 118:102608. PubMed
  24. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  25. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  26. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  27. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  28. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  29. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  30. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  31. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  32. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
  33. Park GY, et al. 2020. Immune Netw. e43:20. PubMed
  34. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  35. Sun Y, et al. 2020. J Immunol. 205:3358. PubMed
  36. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  37. Kenna T, et al. 2008. Blood. 111:2091. PubMed
  38. Clark K, et al. 2019. Front Immunol. 10:2355. PubMed
  39. Karmaus P, et al. 2011. J Leukoc Biol. 90:983. PubMed
  40. Roy S, et al. 2018. Cancer Res. 78:5600. PubMed
  41. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  42. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
  43. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
  44. Cui X, et al. 2017. J Immunol. 199:4066. PubMed
  45. Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed
  46. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  47. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  48. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  49. Richards KA, et al. 2018. Front Immunol. 0.829861111. PubMed
  50. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
  51. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  52. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  53. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  54. Epardaud M, et al. 2008. Cancer Res. 68:2972. PubMed
  55. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  56. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
RRID
AB_313105 (BioLegend Cat. No. 104502)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD69
Specificity Alt (DOES NOT SHOW ON TDS):
CD69
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC-F,IP
UniProt
View information about CD69 on UniProt.org
Go To Top Version: 3    Revision Date: 04/18/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account